^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
PredicineWES+™

Company:
Predicine
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
Predicine’s comprehensive liquid biopsy sequencing solution offers rapid turnaround time for critical clinical applications. From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE or PredicineATLAS focused pan cancer panels, based on tumor fraction from the sample.
Cancer:
Leukemia, Lymphoma, Solid Tumor
Gene:
MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
Method:
Liquid biopsy
Confirmatory trial(s)